Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could Prevention Data Give REGEN-COV Competitive Leg Up?

Executive Summary

Could Prevention Data Give REGEN-COV Competitive Leg Up?

You may also be interested in...



EMA Schedules High-Stakes Oral Explanation Meeting For Aducanumab Filing

The sponsors of aducanumab and three other drugs are set to explain why their EU marketing authorization applications merit approval during oral explanation meetings at the European Medicines Agency.

Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir

Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.

COVID-19 Antibody Cocktail Sweetens Regeneron’s Growth Story

With REGEN-COV in the mix, Regeneron recorded 51% total revenue growth during Q3, including partnership revenue from Roche, but the product’s long-term viability remains in question.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel